# HER2-Positive Gastric Cancer Market Forecast to Reach US$2.05 Billion by 2035 as First-Line Treatment Options Expand | Report by DataM Intelligence

- Link: https://www.thailand-business-news.com/pr-news/her2-positive-gastric-cancer-market-forecast-to-reach-us2-05-billion-by-2035-as-first-line-treatment-options-expand-report-by-datam-intelligence
- Published: 2026-10-21T21:32:00+07:00
- Author: MarketersMEDIA Newswire

_DataM Intelligence’s report analyzes therapy, stage, end-user and regional segments,
including pipeline developments, company positioning and country-level trends. Competition
will increasingly depend on HER2 testing, treatment sequencing and the expansion
of newly approved or clinically advancing regimens across markets._

Leander, Texas, United States, October 21, 2026 /MarketersMEDIA/ — The global [HER2-positive gastric cancer market](https://www.datamintelligence.com/research-report/her2-gastric-cancer-market)
is valued at **US$1.31 billion in 2025** and is forecast to reach **US$2.05 billion
by 2035**, at a **4.6% CAGR**, according to DataM Intelligence. The treatment landscape
is moving beyond a trastuzumab-led approach: antibody-drug conjugates (ADCs), immunotherapy
combinations and bispecific HER2 antibodies are creating new treatment choices across
disease stages and lines of therapy.

The FDA’s August 2026 approval of zanidatamab-based regimens puts HER2 test results
at the center of treatment selection and creates a new competitive challenge for
established trastuzumab combinations. In Japan, where gastric cancer burden is high
and trastuzumab deruxtecan has moved into second-line treatment, the next question
is how quickly emerging first-line regimens can gain local approval and access.

![](https://storage.googleapis.com/mmstudio-images/gallery/R3ukasqFCGcEzUIlHl9CCuLI6a92/
89206870-1792593163-1.jpg)

**Request Executive Sample: [https://www.datamintelligence.com/download-sample/her2-gastric-cancer-market](https://www.datamintelligence.com/download-sample/her2-gastric-cancer-market)**

**United States**

On August 25, the FDA approved zanidatamab with chemotherapy and tislelizumab for
first-line treatment of eligible HER2-positive, unresectable locally advanced or
metastatic gastric, gastroesophageal junction (GEJ) or esophageal adenocarcinoma.
Eligibility includes IHC 3+ or IHC 2+/ISH-positive disease. Zanidatamab with chemotherapy
alone is approved for IHC 3+ tumors. The FDA also approved companion diagnostic 
tests to identify eligible patients. This makes reliable HER2 testing essential 
to access and gives pathology labs a more direct role in treatment selection.

**Japan**

More than 125,000 gastric cancer cases and over 43,000 deaths were recorded in Japan
in 2022, according to Daiichi Sankyo’s release on the country’s treatment update.
In March 2026, Japan expanded trastuzumab deruxtecan (Enhertu) to second-line treatment
for eligible HER2-positive advanced or recurrent gastric cancer, advancing it from
its previous third-line position. Japan also participated in the global HERIZON-
GEA-01 trial; the Japanese trial registry recorded Ehime Prefecture as a study location
and listed the study as no longer recruiting in its October 15 update. U.S. approval
does not establish Japanese approval, so local regulatory status remains a separate
commercial consideration.

**Purchase This Exclusive Report: [https://www.datamintelligence.com/buy-now-page?report=her2-gastric-cancer-market](https://www.datamintelligence.com/buy-now-page?report=her2-gastric-cancer-market)**

**Additional Benefits:**

 ✅ Get Interactive Dashboard Access (With No Additional Cost)

 ✅ Three months of analyst support to answer queries related to the report.

**Recent Developments**

 * **Phase III results strengthened the case for a new first-line HER2 approach.**
   Results from HERIZON-GEA-01, published on May 27, 2026, showed median progression-
   free survival of 12.4 months for both zanidatamab-based treatment arms, compared
   with 8.1 months for trastuzumab plus chemotherapy. The arm combining zanidatamab,
   tislelizumab and chemotherapy reported median overall survival of 26.4 months,
   versus 19.2 months in the control arm.
 * **PD-L1-negative patients remained part of the treatment discussion.** Data presented
   at the 2026 American Society of Clinical Oncology meeting reported benefit with
   zanidatamab, tislelizumab and chemotherapy across PD-L1 subgroups. This may affect
   how companies plan testing and communicate the role of PD-L1 alongside HER2 in
   first-line treatment decisions.
 * **Diarrhea management is an operational consideration.** In HERIZON-GEA-01, diarrhea
   was the most common grade 3 or higher treatment-related adverse event in the 
   zanidatamab-containing arms. The study used anti-diarrheal prophylaxis during
   the first cycle; most events occurred early. Treatment implementation will therefore
   depend in part on clear monitoring and early intervention protocols.
 * **Japan registered a study for tumors expressing both HER2 and CLDN18.2.** The
   ZAP-HETERO phase II study, registered in June 2026, is evaluating zolbetuximab,
   trastuzumab and CapeOX, with pembrolizumab use guided by PD-L1 expression. The
   trial reflects a research question specific to biomarker overlap; it is investigational
   and does not establish an approved treatment.
 * **Japan approved perioperative durvalumab for gastric cancer.** On June 19, 2026,
   Japan approved durvalumab for pre- and post-operative treatment of gastric cancer.
   The approval is not specific to HER2-positive disease, but it signals activity
   in earlier-stage treatment and may influence how companies assess future perioperative
   opportunities.
 * **The FDA approved two first-line zanidatamab regimens on August 25.** Zanidatamab
   with tislelizumab and chemotherapy is approved for HER2 IHC 3+ or IHC 2+/ISH-
   positive disease. Zanidatamab with chemotherapy alone is approved for IHC 3+ 
   disease. The distinction makes the testing threshold central to treatment eligibility.
 * **The FDA also approved companion diagnostic devices.** The PATHWAY anti-HER-
   2/neu (4B5) antibody and VENTANA HER2 Dual ISH DNA Probe Cocktail were approved
   to identify patients eligible for the zanidatamab regimens. The decision links
   treatment access directly to validated testing workflows.

**Market Segmentation:**

**Targeted therapy represented 38.6% of 2025 market revenue**, equal to about US
$506 million on the report’s US$1.31 billion market base. This segment includes 
HER2-directed treatment such as trastuzumab and ADCs. First-line bispecific antibody
and immunotherapy combinations are now adding competition within this established
targeted-treatment pool.

**Stage IV disease accounted for 41.2% of 2025 revenue**, or about US$540 million
on the same base. The segment’s share reflects the use of systemic therapies in 
advanced disease, including multiple treatment lines. New first-line approvals and
second-line ADC access in Japan may reshape how revenue is distributed across regimens
and treatment stages.

**Company Profiles**

**Jazz Pharmaceuticals** commercializes zanidatamab in the United States and other
territories covered by its license. The FDA’s first-line approval gives Jazz a broader
role in HER2-positive gastroesophageal adenocarcinoma beyond the drug’s existing
biliary-tract-cancer indication. Execution will depend on uptake of the new combination
regimen and on access to HER2 testing.

**BeOne Medicines** supplies tislelizumab (Tevimbra), the PD-1 inhibitor included
in the approved triplet regimen. Its collaboration with Jazz on HERIZON-GEA-01 and
the trial’s published results position the company as both a treatment partner and
a contributor to first-line clinical evidence.

**Zymeworks** engineered and first developed zanidatamab, then licensed development
and commercialization rights to Jazz and BeOne by territory. Its 2025 Form 10-K 
describes potential tiered royalties and milestone payments tied to the partners’
sales and regulatory progress, giving Zymeworks an ongoing economic interest in 
the drug’s commercial expansion.

**Daiichi Sankyo and AstraZeneca** jointly develop and commercialize trastuzumab
deruxtecan (Enhertu). In Japan, Daiichi Sankyo commercializes the ADC and expanded
its gastric-cancer use to second-line treatment in March 2026. The product remains
a central comparator as new first-line combinations enter the market.

**Request a Customized Report According to Your Business Strategy: [https://www.datamintelligence.com/customize/her2-gastric-cancer-market](https://www.datamintelligence.com/customize/her2-gastric-cancer-market)**

Contact Info: 
Name: Sai KiranEmail: [Send Email](https://send.releasecontact.com/89206870)
Organization: DataM Intelligence 4Market Research LLPAddress: 2243 Rocoso TRL, Leander
TX 78641Phone: +1 877 441 4866Website: [https://www.datamintelligence.com/](https://www.datamintelligence.com/)

Release ID: 89206870

Should any problems, inaccuracies, or doubts arise from the content contained within
this press release, we kindly request that you inform us immediately by contacting
[error@releasecontact.com](https://www.thailand-business-news.com/pr-news/error@releasecontact.com)(
it is important to note that this email is the authorized channel for such matters,
sending multiple emails to multiple addresses does not necessarily help expedite
your request). Our dedicated team will promptly address your concerns within 8 hours,
taking necessary steps to rectify identified issues or assist with the removal process.
Providing accurate and dependable information is at the core of our commitment to
our readers.

**Source** : [HER2-Positive Gastric Cancer Market Forecast to Reach US$2.05 Billion by 2035 as First-Line Treatment Options Expand | Report by DataM Intelligence](https://news.marketersmedia.com/her2-positive-gastric-cancer-market-forecast-to-reach-usdollar205-billion-by-2035-as-first-line-treatment-options-expand-or-report-by-datam-intelligence/89206870?rand=206000)

    ```wp-block-verse
    The information provided in this article was created by MarketersMEDIA Newswire, our news partner. The author's opinions and the content shared on this page are their own and may not necessarily represent the perspectives of Thailand Business News.
    ```